A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients

被引：0
|
作者：
Rajiv Kumar
Shir Kiong Lu
Anna Minchom
Adam Sharp
Michael Davidson
Ranga Gunapala
Timothy A. Yap
Jaishree Bhosle
Sanjay Popat
Mary E. R. O’Brien
机构：
[1] The Royal Marsden NHS Foundation Trust,Department of Medicine
[2] The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 77卷
关键词：
Non-small cell lung cancer; Adenocarcinoma; Capecitabine; Erlotinib; Phase 1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：375 / 383
页数：8
相关论文
共 50 条
  • [21] A multicenter, open-label, phase IIIB trial of erlotinib in patients with advanced non-small cell lung cancer
    Hainsworth, J
    Spigel, D
    O'Neill, V
    Klencke, B
    LUNG CANCER, 2005, 49 : S246 - S247
  • [22] Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer
    Gerber, David E.
    Boothman, David A.
    Fattah, Farjana J.
    Dong, Ying
    Zhu, Hong
    Skelton, Rachel A.
    Priddy, Laurin L.
    Vo, Peggy
    Dowell, Jonathan E.
    Sarode, Venetia
    Leff, Richard
    Meek, Claudia
    Xie, Yang
    Schiller, Joan H.
    LUNG CANCER, 2015, 90 (03) : 534 - 541
  • [23] PHASE II TRIAL OF ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Okano, Yoshio
    Shinohara, Tsutomu
    Machida, Hisanori
    Hatakeyama, Nobuo
    Takeuchi, Eiji
    Doi, Hiroyuki
    Kubota, Tetsuya
    Yokoyama, Akihito
    Ogushi, Fumitaka
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1175 - S1176
  • [24] ERLOTINIB FOR CHINESE ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Wang, H-P
    Li, Z.
    Wang, M-Z
    Yi, X.
    RESPIROLOGY, 2011, 16 : 172 - 172
  • [25] Erlotinib (Tarceva) for advanced non-small cell lung cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2005, 47 (1205): : 25 - 26
  • [26] Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases
    Kaneda, Hiroyasu
    Sawa, Kenji
    Daga, Haruko
    Okada, Asuka
    Nakatani, Yuki
    Atagi, Shinji
    Okishio, Kyoichi
    Tani, Yoko
    Matsumoto, Yoshiya
    Ogawa, Koichi
    Nakahama, Kenji
    Izumi, Motohiro
    Mitsuoka, Shigeki
    Kawaguchi, Tomoya
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1598 - 1603
  • [27] Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
    Ou, Sai-Hong Ignatius
    Govindan, Ramaswamy
    Eaton, Keith D.
    Otterson, Gregory A.
    Gutierrez, Martin E.
    Mita, Alain C.
    Argiris, Athanassios
    Brega, Nicoletta M.
    Usari, Tiziana
    Tan, Weiwei
    Ho, Steffan N.
    Robert, Francisco
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : 145 - 151
  • [28] Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer
    Halmos, Balazs
    Pennell, Nathan A.
    Fu, Pingfu
    Saad, Shumaila
    Gadgeel, Shirish
    Otterson, Gregory A.
    Mekhail, Tarek
    Snell, Michael
    Kuebler, Philip
    Sharma, Neelesh
    Dowlati, Afshin
    ONCOLOGIST, 2015, 20 (11): : 1298 - 1303
  • [29] Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer
    Elisabetta Campagnoli
    Isabella Garassino
    Armando Santoro
    Fabio De Vincenzo
    Paolo Andrea Zucali
    Giovanni Luca Ceresoli
    Fabio Romano Lutman
    Marco Alloisio
    Hector Josè Soto Parra
    Raffaele Cavina
    Investigational New Drugs, 2007, 25 : 559 - 564
  • [30] Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer
    Campagnoli, Elisabetta
    Garassino, Isabella
    Santoro, Armando
    De Vincenzo, Fabio
    Zucali, Paolo Andrea
    Ceresoli, Giovanni Luca
    Lutman, Fabio Romano
    Alloisio, Marco
    Parra, Hector Jose Soto
    Cavina, Raffaele
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (06) : 559 - 564
12345